Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) EPS (Basic) (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of EPS (Basic) data on record, last reported at -$0.1 in Q1 2026.

  • On a quarterly basis, EPS (Basic) rose 33.33% to -$0.1 in Q1 2026 year-over-year; TTM through Mar 2026 was -$0.43, a 27.12% increase, with the full-year FY2025 number at -$0.49, up 57.76% from a year prior.
  • EPS (Basic) reached -$0.1 in Q1 2026 per IKT's latest filing, down from -$0.09 in the prior quarter.
  • Over the last five years, EPS (Basic) for IKT hit a ceiling of $0.87 in Q4 2024 and a floor of -$1.11 in Q2 2023.
  • A 5-year average of -$0.51 and a median of -$0.66 in 2024 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): tumbled 488.89% in 2022, then surged 227.94% in 2024.
  • Tracing IKT's EPS (Basic) over 5 years: stood at -$1.02 in 2022, then soared by 33.33% to -$0.68 in 2023, then surged by 227.94% to $0.87 in 2024, then tumbled by 110.34% to -$0.09 in 2025, then fell by 11.11% to -$0.1 in 2026.
  • Business Quant data shows EPS (Basic) for IKT at -$0.1 in Q1 2026, -$0.09 in Q4 2025, and -$0.13 in Q3 2025.